In 2019, Mike Blevins felt a deep, sharp pain in his side and went to a nearby hospital, where he was diagnosed with kidney cancer. He called his daughter, a surgical tech, who told him to get a second opinion. The second doctor confirmed the diagnosis, found that the cancer had metastasized, and recommended a clinical trial combining two immunotherapies: ipilimumab (Yervoy®) and nivolumab (Opdivo®). After another conversation with his family, Mike decided to enroll and, over the course of 10 months, the tumor shrank from 7.8cm to just about 3cm. After two years of stability, the tumors started to grow again and he began a new regimen combining a different immunotherapy, pembrolizumab (Keytruda®), with chemotherapy. Recently retired, Mike now enjoys time with his kids and grandchildren, grateful to his family for their lifesaving advice and support along the way. He is happy to share his immunotherapy experience as a CRI ImmunoAdvocate.